Read by QxMD icon Read

Clinical Breast Cancer

Dr Kadri Altundag
No abstract text is available yet for this article.
January 23, 2019: Clinical Breast Cancer
Bernardo Cacho-Díaz, Héctor Spínola-Maroño, Nancy Reynoso, Alberto González-Aguilar, Alejandro Mohar-Betancourt
INTRODUCTION: Breast cancer (BC) is the most common cancer in women, and the incidence of brain metastasis (BM) from BC ranges from 20% to 30%, with a median survival of 10 to 15 months. Previous reports have shown that the presence of obesity or diabetes negatively impacts survival. The present study investigates the association between obesity or diabetes mellitus (DM) and overall survival of patients with BC with BM. MATERIALS AND METHODS: A database from 2 referral centers for the period of July 2014 to February 2018 was analyzed...
January 7, 2019: Clinical Breast Cancer
Tarek M K Motawi, Nadia I Zakhary, Hebatallah A Darwish, Hassan M Abdalla, Samer A Tadros
BACKGROUND: Breast cancer is one of the most relevant malignancies among women. Molecular abnormalities in promotor region of survivin gene may account for overexpression of survivin and increased breast cancer risk. This study aimed to explore the potential association between survivin promotor gene -31G/C single nucleotide polymorphism (rs9904341) and its serum level alteration on one hand, and the risk of breast cancer in Egyptian patients on the other hand. It also aimed to assess the usefulness of survivin as an early noninvasive diagnostic biomarker and in breast cancer staging...
January 6, 2019: Clinical Breast Cancer
Fernando A Angarita, Sergio A Acuna, Nancy Down, Chung Shan Leung, Farahnaz Pirmoradi, Fahima Osman
BACKGROUND: Most data comparing wire localized excision (WLE) and radioactive seed localized excision (RSLE) derive from academic institutions with limited data from community hospitals. This study aimed to compare positive margin rates between WLE and RSLE and to determine if there were any differences in specimen volume and operation time. PATIENTS AND METHODS: A retrospective cohort study was conducted on patients who underwent WLE or RSLE at a Canadian community hospital...
January 6, 2019: Clinical Breast Cancer
Elisavet Paplomata, Amelia Zelnak, Cesar A Santa-Maria, Yuan Liu, Keerthi Gogineni, Xiaoxian Li, Carlos S Moreno, Zhengjia Chen, Virginia Kaklamani, Ruth M O'Regan
BACKGROUND: Increased signaling through growth factor receptor pathways, including HER2, plays a role in resistance to endocrine therapy (ET) in patients with hormone receptor (HR)-positive metastatic breast cancer (MBC). Inhibition of mechanistic target of rapamycin improves outcomes when used in addition to ET in patients with HR-positive MBC, who previously received ET. We hypothesized that the additional use of trastuzumab (T) or everolimus (E) could restore sensitivity to ET in patients with endocrine-resistant, HR-positive, HER2-negative MBC...
January 3, 2019: Clinical Breast Cancer
Roy de Vita, Ernesto Maria Buccheri, Amedeo Villanucci, Marcello Pozzi
BACKGROUND: Implant-based breast reconstruction after nipple-sparing mastectomy has been the most common breast reconstruction procedure performed, for both breast cancer treatment and prophylactically. Subpectoral implant placement with partial detachment of the pectoralis major muscle has been the procedure of choice for staged reconstruction and direct-to-implantation. Prepectoral implant placement has recently increased in popularity among plastic surgeons owing to the high rates of animation deformity, loss of muscle function, and chronic pain observed with submuscular implant placement...
December 27, 2018: Clinical Breast Cancer
Sarah Colonna, John Sweetenham, Trever B Burgon, Saundra S Buys, Ray Lynch, Trang Au, Eric Johnson, Timothy Kubal, David Paculdo, Maria Czarina Acelajado, John W Peabody
INTRODUCTION: Unwanted clinical variation is common across the United States health care system and is particularly vexing in oncology owing to the complexity, morbidity, and high cost of the disease. Efforts to standardize care including guidelines and continuing medical education have had only limited impact. Disease-specific oncology clinical pathways hold the promise of reducing variation but have been hampered by a lack of ownership and accountability among oncology providers. MATERIALS AND METHODS: We describe the utility of combining a patient simulation-based clinical variation measurement with the in-house development of multidisciplinary breast cancer pathways at a National Cancer Institute-designated cancer center...
December 21, 2018: Clinical Breast Cancer
Essam Eldin Mohamed Nour Eldin, Mahmoud Zaki El-Readi, Mohamed Mahmoud Nour Eldein, Albagir Ali Alfalki, Mohammad Ahmad Althubiti, Hala Fawzy Mohamed Kamel, Safaa Yehia Eid, Hiba Saeed Al-Amodi, Ahmad A Mirza
BACKGROUND: Breast cancer (BC) is one of the most prevalent and reported cancers among Saudi women. Detection of BC in the early invasive stage (stages I, II) has an advantage in treating patients over detection in the late invasive stage (stages III, IV). Tumor markers are used to aid in diagnosis, treatment monitoring, and recurrence detection of malignant tumors. 8-hydroxy-2'-deoxyguanosine (8-OHdG) is a marker of nucleic damage owing to oxidative stress. PATIENTS AND METHODS: We studied the blood levels of 8-OHdG in 50 women with benign breast tumors, 50 women with BC, and 50 healthy women as a control group...
December 21, 2018: Clinical Breast Cancer
Sarah-May Blaschke, Karla C Gough, Boon H Chua, Prudence A Francis, Robyn Cockerell, Allison F Drosdowsky, Lisa Sheeran, Meinir Krishnasamy
INTRODUCTION: The present study examined the feasibility and effects of integrating a multidisciplinary team (MDT) model of care for women with metastatic breast cancer (MBC) into a large Australian cancer center. The challenges encountered and lessons learned are described. PATIENTS AND METHODS: In the present prospective, longitudinal, mixed-methods implementation study, the MDT model included face-to-face consultations with a breast care nurse and social worker, followed by a MDT case discussion and face-to-face delivery of a personalized management plan...
December 21, 2018: Clinical Breast Cancer
Vanesa Ortega, Antonio Antón, Isabel Garau, Noemia Afonso, Lourdes Calvo, Yolanda Fernández, María Martínez-García, Esperanza Blanco, Pilar Zamora, Mirta García, José Juan Illarramendi, César Augusto Rodríguez Sánchez, Miguel Sampayo, Elena Aguirre, José Manuel Pérez-García, Javier Cortés, Antonio Llombart-Cussac
BACKGROUND: Eribulin has efficacy in patients with progression after ≥ 1 chemotherapeutic regimen for metastatic breast cancer (MBC). A short disease-free interval (DFI) and previous use of taxanes in the neoadjuvant or adjuvant setting have been associated with worse outcomes for patients receiving first-line chemotherapy for HER2-negative MBC. The aim of the present trial was to evaluate the efficacy and safety of eribulin as first-line therapy for patients with HER2-negative MBC with these poor prognostic factors...
December 20, 2018: Clinical Breast Cancer
Kimberly L Blackwell, Khalil Zaman, Shukui Qin, Katherine H R Tkaczuk, Mario Campone, Daniel Hunt, Richard Bryce, Lori J Goldstein
BACKGROUND: Despite the availability of several human epidermal growth factor receptor 2 (HER2)-directed treatments, many HER2-positive (HER2+ ) breast cancers eventually progress because of primary or acquired resistance. PATIENTS AND METHODS: A 2-part, open-label, multicenter phase I/II study was conducted to determine the recommended dose of neratinib when administered with trastuzumab (part I), and to assess the antitumor activity of this combination in women with locally advanced or metastatic HER2+ breast cancer previously treated with at least 1 prior trastuzumab-based regimen (part II)...
December 20, 2018: Clinical Breast Cancer
Sara Tanini, Alessandra D Fisher, Icro Meattini, Simonetta Bianchi, Jiska Ristori, Mario Maggi, Giulia Lo Russo
No abstract text is available yet for this article.
December 20, 2018: Clinical Breast Cancer
Ayush K Kapila, Allison Herd, Natalie Knife, Pauly Chaplin, Ashraf Patel
INTRODUCTION: Breast cancer treatment and recovery remain physically and psychologically challenging for patients. Reflexology has been studied as a complementary therapy to help relieve patients of the physical and psychological stresses involved with breast cancer. As a result of recent positive evidence, we studied its effects quantitatively from 2015 to 2016. PATIENTS AND METHODS: Fifty-two patients completed pre- and post-reflexology intervention 'Measure Yourself Concerns and Wellbeing' (MYCaW) questionnaires...
December 19, 2018: Clinical Breast Cancer
Bo Lan, Fei Ma, Mei Han, Shanshan Chen, Wenna Wang, Qiao Li, Ying Fan, Yang Luo, Ruigang Cai, Jiayu Wang, Peng Yuan, Pin Zhang, Qing Li, Binghe Xu
INTRODUCTION: UGT1A4 is a major enzyme responsible for the glucuronidation of tamoxifen (TAM) and its metabolites. Genetic variations in the UGT1A4 gene could have a significant impact on the clinical efficacy of TAM. This study was performed to validate the association between UGT1A4 polymorphisms and the clinical outcomes for patients with breast cancer who received adjuvant TAM. PATIENTS AND METHODS: A total of 773 patients with breast cancer who received adjuvant TAM (n = 321) or aromatase inhibitors (n = 452) at the National Cancer Center in China were analyzed...
December 19, 2018: Clinical Breast Cancer
Lynn Symonds, Hannah Linden, Vijayakrishna Gadi, Larissa Korde, Eve Rodler, Julie Gralow, Mary Redman, Kelsey Baker, Quan Vicky Wu, Isaac Jenkins, Brenda Kurland, Mitchell Garrison, Julie Smith, Jeanne Anderson, Carol Van Haelst, Jennifer Specht
INTRODUCTION: Angiogenesis and epidermal growth factor receptor signaling are potential therapeutic targets in triple negative breast cancer (TNBC). We hypothesized that targeting these critical pathways would prolong progression-free survival with first-line therapy for metastatic TNBC. PATIENTS AND METHODS: We conducted a phase II trial of nab-paclitaxel and bevacizumab, followed by maintenance therapy with bevacizumab and erlotinib, for patients with metastatic TNBC...
December 14, 2018: Clinical Breast Cancer
Kaifeng Deng, Shanying Mo, Xuexiang Liu, Jifei Chen, Qiaoyun Zhang, Xiaoli Chen, Jianming Chen, Shengming Dai
BACKGROUND: Based on estrogen active substances, many women consume soy foods in the belief that it could prevent breast cancer (BC). Women with different molecular subtypes would be likely to have diverse reactions to soy foods, especially those with the estrogen-receptor-positive (ER+ ) subtype. The aim of the current study is to identify the differentially expressed genes (DEGs) on soy foods in premenopausal patients with Lumina A subtype of BC (LABC) after soy food treatment, and to further investigate the critical molecule change...
December 12, 2018: Clinical Breast Cancer
Claudio Vernieri, Michele Prisciandaro, Monica Milano, Maria Silvia Cona, Claudia Maggi, Marta Brambilla, Alessia Mennitto, Chiara Fabbroni, Elena Farè, Sara Cresta, Luigi Celio, Gabriella Mariani, Giulia Bianchi, Giuseppe Capri, Filippo de Braud
BACKGROUND: Single-agent gemcitabine is a moderately effective compound in metastatic breast cancer (mBC) treatment. Carboplatin is frequently used in addition to gemcitabine to improve tumor responses, but with an unclear effect on survival outcomes. In this study we evaluated the antitumor efficacy and safety profiles of gemcitabine and carboplatin-gemcitabine in mBC patients. PATIENTS AND METHODS: We retrospectively collected data on patients treated between April 2012 and February 2018 with gemcitabine 800 mg/m2 or carboplatin at an area under the curve of 2 with gemcitabine 800 mg/m2 , given on days 1 and 8 every 21 days...
December 12, 2018: Clinical Breast Cancer
Omar Abdel-Rahman, Yuan Xu, Shiying Kong, Joseph Dort, May Lynn Quan, Safiya Karim, Antoine Bouchard-Fortier, HyoKeun Cho, Winson Y Cheung
INTRODUCTION: The aim of this study was to characterize treatment trends and outcomes of women who have preexisting cardiovascular disease (CVD) prior to the diagnosis of breast cancer. PATIENTS AND METHODS: This represented a retrospective, population-based cohort study that analyzed pooled data from the provincial cancer registry, physician billing claims, hospital discharge abstracts, ambulatory care, and the 2011 census in a large Canadian province. Multivariable logistic regression was performed to identify the associations of CVD with breast cancer treatment and outcomes...
December 12, 2018: Clinical Breast Cancer
Sidra N Bonner, Cheryl Clark, Nancy L Keating, Elena M Kouri, Rachel A Freedman
BACKGROUND: The effect of racial residential segregation on breast cancer treatment disparities is unclear. We examined whether racial segregation is associated with adjuvant treatment receipt and patient knowledge of disease. PATIENTS AND METHODS: We surveyed a population-based sample of women in Northern California with stage I to III breast cancer diagnosed in 2010 to 2011 (participation rate = 68.5%, 500 patients). For black, Hispanic, and white women, we measured black and Hispanic segregation using the location quotient (LQ) of racial residential segregation, a proportional measure of the size of a minority group in the census tract compared with the larger metropolitan statistical area...
December 8, 2018: Clinical Breast Cancer
Chiara Adriana Pistolese, Antonella Castrignanò, Francesca Ricci, Rosaria Meucci, Giusy Croce, Mariateresa Mondillo, Alberto Collura, Tommaso Perretta, Roberto Floris
BACKGROUND: The study aimed to evaluate the feasibility and reliability of ultrasound-guided vacuum-assisted breast biopsy (US-VABB) for sampling of microcalcifications indicative of cancer when stereotactic vacuum-assisted breast biopsy cannot be performed because of reasons such as thin breast tissue, insufficient thickness at compression, and microcalcification situated close to the chest wall or in breast tissue of the axillary tail. PATIENTS AND METHODS: The study population was selected from among 187 patients with microcalcifications detected on mammogram...
December 7, 2018: Clinical Breast Cancer
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"